ANEB Valuation

Anebulo Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

2.540

-0.1(-3.788%)1D

ANEB Relative Valuation

ANEB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ANEB is overvalued; if below, it's undervalued.

Historical Valuation

Anebulo Pharmaceuticals Inc (ANEB) is now in the Fair zone, suggesting that its current forward PS ratio of 2.64 is considered Fairly compared with the five-year average of -7.84. The fair price of Anebulo Pharmaceuticals Inc (ANEB) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：2.64

Fair

-5.29

Trailing

Forward

0.00

EV/EBITDA

Anebulo Pharmaceuticals Inc. (ANEB) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-6.65

EV/EBIT

Anebulo Pharmaceuticals Inc. (ANEB) has a current EV/EBIT of -6.65. The 5-year average EV/EBIT is -7.45. The thresholds are as follows: Strongly Undervalued below -23.26, Undervalued between -23.26 and -15.35, Fairly Valued between 0.46 and -15.35, Overvalued between 0.46 and 8.36, and Strongly Overvalued above 8.36. The current Forward EV/EBIT of -6.65 falls within the Historic Trend Line -Fairly Valued range.

2.54

Anebulo Pharmaceuticals Inc. (ANEB) has a current PS of 2.54. The 5-year average PS is 0.02. The thresholds are as follows: Strongly Undervalued below -0.39, Undervalued between -0.39 and -0.19, Fairly Valued between 0.22 and -0.19, Overvalued between 0.22 and 0.42, and Strongly Overvalued above 0.42. The current Forward PS of 2.54 falls within the Strongly Overvalued range.

81.12

P/OCF

Anebulo Pharmaceuticals Inc. (ANEB) has a current P/OCF of 81.12. The 5-year average P/OCF is -5.12. The thresholds are as follows: Strongly Undervalued below -40.95, Undervalued between -40.95 and -23.04, Fairly Valued between 12.79 and -23.04, Overvalued between 12.79 and 30.70, and Strongly Overvalued above 30.70. The current Forward P/OCF of 81.12 falls within the Strongly Overvalued range.

-3.22

P/FCF

Anebulo Pharmaceuticals Inc. (ANEB) has a current P/FCF of -3.22. The 5-year average P/FCF is -5.68. The thresholds are as follows: Strongly Undervalued below -22.13, Undervalued between -22.13 and -13.90, Fairly Valued between 2.55 and -13.90, Overvalued between 2.55 and 10.78, and Strongly Overvalued above 10.78. The current Forward P/FCF of -3.22 falls within the Historic Trend Line -Fairly Valued range.

Anebulo Pharmaceuticals Inc (ANEB) has a current Price-to-Book (P/B) ratio of 9.30. Compared to its 3-year average P/B ratio of 8.94 , the current P/B ratio is approximately 4.05% higher. Relative to its 5-year average P/B ratio of -10.32, the current P/B ratio is about -190.17% higher. Anebulo Pharmaceuticals Inc (ANEB) has a Forward Free Cash Flow (FCF) yield of approximately -5.85%. Compared to its 3-year average FCF yield of -13.49%, the current FCF yield is approximately -56.62% lower. Relative to its 5-year average FCF yield of -10.67% , the current FCF yield is about -45.15% lower.

8.95

P/B

Median3y

8.94

Median5y

-10.32

-0.06

FCF Yield

Median3y

-13.49

Median5y

-10.67

Competitors Valuation Multiple

The average P/S ratio for ANEB's competitors is 4.91, providing a benchmark for relative valuation. Anebulo Pharmaceuticals Inc Corp (ANEB) exhibits a P/S ratio of 2.54, which is -48.30% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ANEB.O

Anebulo Pharmaceuticals Inc

Alterity Therapeutics Ltd

6.16

73.05M

IKT.O

Inhibikase Therapeutics Inc

Atara Biotherapeutics Inc

13.85

-38.63%

97.27M

Performance Decomposition

Market capitalization of ANEB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ANEB in the past 1 year is driven by Unknown.